Monday, November 23, 2009, 7:25PM AEST - The Australian Stockmarket is closed.
To create a watchlist or portfolio of shares, Register

Ardea Biosciences, Inc. (RDEA)

On Nov 21: 13.68 USD   0.00 (0.00%)  
 MORE ON RDEA 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Ardea Biosciences, Inc. (NGM:RDEA) Delayed quote dataEdit
Last Trade:13.68 USD
Trade Time:Nov 21
Change: 0.00 (0.00%)
Prev Close:13.68
Open:N/A
Bid:N/A
Ask:N/A
1y Target Est:25.25
Day's Range:N/A - N/A
52wk Range:6.29 - 21.35
Volume:0
Avg Vol (3m):88,106.1
Market Cap:251.92M
P/E (ttm):N/A
EPS (ttm):-2.14
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add RDEA to Portfolio   Download Data

 HEADLINES 
ARDEA BIOSCIENCES, INC./DE Financials
EDGAR Online Financials (Sat, Nov 14)
New Star Analyst Rankings for Ardea Biosciences, Inc.
StarMine (Wed, Nov 11)
ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online (Sat, Nov 7)
Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
PR Newswire (Sat, Nov 7)
ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Regulation FD Disclosure
EDGAR Online (Wed, Nov 4)
Ardea Biosciences to Present at Three Upcoming Investor Conferences
Business Wire (Wed, Oct 28)
Ardea Presents Gout Data
Zacks.com (Fri, Oct 23)
ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Regulation FD Disclosure
EDGAR Online (Mon, Oct 19)
Ardea Biosciences Announces Additional Positive Results from a Phase 2a Study of RDEA594 at the 2009 ACR/ARHP Annual Scientific Meeting
Business Wire (Mon, Oct 19)
Ardea Biosciences to Present Results from a Phase 2a Study of RDEA594 at the 2009 ACR/ARHP Annual Scientific Meeting
Business Wire (Wed, Sep 30)
Ardea Biosciences to Present at Three Upcoming Investor Conferences
Business Wire (Wed, Sep 16)
More Headlines for RDEA...

 ANALYST 
EPS Est (next year) (Dec-09) :-1.59
EPS Est (in 2 years) (Dec-10) :-2.12
Avg Rec (current)*:1.4
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), cancer, and inflammatory diseases in the United States.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices